文献速递主动脉疾病

不同主动脉病理类型患者行胸主动脉腔内修复术(TEVAR)的长期结局与危险因素分析

Long-Term Outcomes and Risk Factors Analysis for Patients Undergoing Thoracic Endovascular Aorta Repair (TEVAR), According to the Aortic Pathologies.
PubMed 文献 · Ann Vasc Surg · 2023-03-11

本研究前瞻性收集并回顾性分析2002年6月至2020年4月本机构116例因不同胸主动脉疾病行TEVAR患者的资料。结果显示生存率因TEVAR适应证而异(log rank P=0.024),既往A型夹层治疗后者5年生存率最差为50%,动脉瘤性主动脉疾病5年生存率为55%,创伤组无晚期死亡。Cox回归识别出年龄、男性、中度慢性阻塞性肺疾病、既往心脏手术及动脉瘤治疗适应证为死亡的独立预测因素。

要点

  • TEVAR术后长期生存因主动脉病理类型不同而异,log rank P=0.024。
  • 既往A型夹层治疗组5年生存率50%,动脉瘤性主动脉疾病组5年生存率55%。
  • 创伤性主动脉损伤组无晚期死亡,患者更年轻且合并症更少。

核心结论

  • TEVAR在创伤性主动脉损伤中安全有效且长期结果优良,总体长期生存受主动脉病理、合并症、性别及既往心脏手术影响。

研究设计与样本

  • 本机构前瞻性收集并回顾性分析2002年6月至2020年4月116例行TEVAR的胸主动脉疾病患者资料。
  • 采用Kaplan-Meier法确定总体生存,log-rank检验比较组间生存,Cox回归分析识别危险因素。

主要发现

  • 116例中,动脉瘤性主动脉疾病47例(41%),B型主动脉夹层26例(22%),穿透性主动脉溃疡23例(20%),既往A型夹层治疗后11例(9%),创伤性主动脉损伤9例(8%)。
  • 创伤性主动脉损伤患者更年轻(P < 0.01),高血压(P < 0.01)、糖尿病(P < 0.01)及既往心脏手术(P < 0.01)更少。
  • 生存率因TEVAR适应证而异(log rank P=0.024),既往A型夹层治疗组5年生存率50%,动脉瘤性主动脉疾病组5年生存率55%,创伤组无晚期死亡。
  • Cox回归识别死亡的独立预测因素:年龄(HR 1.05,95%CI 1.01-1.09,P=0.006)、男性(HR 3.2,95%CI 1.1-9.2,P=0.028)、中度慢性阻塞性肺疾病(HR 2.1,95%CI 1.02-4.55,P=0.043)、既往心脏手术(HR 2.1,95%CI 1.008-4.5,P=0.048)、动脉瘤治疗适应证(HR 2.6,95%CI 1.2-5.2,P=0.008)。

临床怎么用

  • 作者认为TEVAR在创伤性主动脉损伤中安全有效且长期结果优良,总体长期生存受主动脉病理、合并症、性别及既往心脏手术影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thoracic endovascular aortic repair (TEVAR) has become a standard treatment for acute and chronic thoracic aorta diseases. We analyzed long-term outcomes and risk factors of TEVAR procedures according to the aortic pathology. METHODS: Demographics, indications, technical details, and outcomes of patients undergoing TEVAR procedures in our institutions were prospectively collected and retrospectively analyzed. Overall survival was determined using Kaplan-Meier methods while log-rank tests were used to compare the survival between groups. Cox regression analysis was used to identify risk factors. RESULTS: Between June 2002 and April 2020, 116 patients underwent TEVAR for different thoracic aorta diseases. Among them, 47 patients (41%) underwent TEVAR for aneurysmatic aortic disease, 26 (22%) for type-B aortic dissection, 23 (20%) for penetrating aortic ulcer, 11 (9%) after previous type-A dissection treatment, and 9 (8%) for traumatic aortic injury. Patients with posttraumatic aortic injury were younger (P < 0.01) with less hypertension (P < 0.01), diabetes (P < 0.01), and prior cardiac surgery (P < 0.01). Survival was different based on indication for TEVAR (log rank 0.024). Patients after previous type-A dissection treatment had the worst survival rate (50% at 5 years) while survival for aneurysmatic aortic disease was 55% at 5 years. No late death occurred in the traumatic group. Cox-regression model identified independent predictors for mortality: age (hazard ratio [HR]: 1.05, 95% confidence interval [CI]: 1.01-1.09, P = 0.006), male gender (HR: 3.2, 95% CI: 1.1-9.2, P = 0.028), moderate chronic obstructive pulmonary disease (HR: 2.1, 95% CI: 1.02-4.55, P = 0.043), previous cardiac surgery (HR: 2.1, 95% CI: 1.008-4.5, P = 0.048), and treatment indication for aneurysm (HR: 2.6, 95% CI: 1.2-5.2, P = 0.008). CONCLUSIONS: TEVAR is a safe and effective procedure with excellent long-term results in case of traumatic aortic injury. The overall long-term survival is affected by aortic pathology, associated comorbidities, gender, and previous cardiac surgery.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Gallo M, van den Berg JC, Torre T, et al. Long-Term Outcomes and Risk Factors Analysis for Patients Undergoing Thoracic Endovascular Aorta Repair (TEVAR), According to the Aortic Pathologies. Ann Vasc Surg. 2023. PMID: 36907507. doi:10.1016/j.avsg.2023.02.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。